AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Bright Minds Biosciences Inc (NASDAQ:DRUG)
74.24 USD
-2.540 3.308%Sponsored Reports
Loading...
| Previous Close (in USD) | 76.78 |
|---|---|
| Change | -2.540 3.308% |
| 52 W H/L (in USD) | 123.750/23.175 |
| EBITDA (in USD) | -- |
| PE Ratio | -- |
| Volume | 753692 |
| Diluted Eps TTM | -2.01 |
| Total Assets (in USD) | 84.422M |
|---|---|
| Total Liabilities (in USD) | 2.377M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 82.909M |
| Market Cap (in USD) | 888.576 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | -- |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Bright Minds Biosciences Inc
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Employees: 26
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Ian McDonald | Co-Founder, CEO, Pres & Director | 1988 |
| 2. | Mr. Ryan E. S. K. Cheung B.Com., CA, CPA | Chief Financial Officer | 1978 |
| 3. | Dr. Emer Leahy M.B.A., Ph.D. | Consultant | 1967 |
| 4. | Dr. Jan Torleif Pedersen M.Sc., Ph.D. | Interim Chief Science Officer & Director | NA |
| 5. | Dr. Mark A. Smith M.D., Ph.D. | Chief Medical Officer | 1955 |
| 6. | Dr. Gideon Shapiro Ph.D. | VP of Discovery | NA |
| 7. | Mr. Ian McDonald | Co-Founder, CEO, President & Director | 1989 |
| 8. | Dr. Jan Torleif Pedersen M.Sc., Ph.D. | Chief Science Officer & Director | 1965 |
| 9. | Mr. Ian McDonald | Co-Founder, CEO, President & Director | 1988 |
| 10. | Mr. Alex Vasilkevich | COO & Senior Scientific Officer | 1989 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.920 2.144% | 42.715 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.750 1.734% | 42.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+3.250 0.765% | 420.63 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+16.030 2.659% | 600.79 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 30-09-2025 | 30-09-2024 | 30-09-2023 | 30-09-2022 | 30-09-2021 |
|---|---|---|---|---|---|
| Income Before Tax | -12.229M | -2.802M | -7.372M | -14.965M | -8.651M |
| Minority Interest | - | - | - | - | - |
| Net Income | -12.229M | -2.802M | -7.372M | -15.188M | -8.515M |
| Selling General Administrative | 2.136M | 1.404M | 2.08M | 1.999M | 1.438M |
| Gross Profit | -0.077M | - | -0.072M | - | - |
| Reconciled Depreciation | 0.077M | 0.073M | 0.072M | 0.006M | - |
| Ebit | -13.938M | -2.823M | -7.386M | -14.742M | -8.623M |
| Ebitda | -13.861M | -2.749M | -7.314M | -14.736M | -8.759M |
| Depreciation And Amortization | 0.077M | 0.073M | 0.072M | 0.006M | - |
| Operating Income | -13.938M | -2.823M | -7.386M | -14.742M | -8.759M |
| Other Operating Expenses | 13.938M | 2.823M | 7.386M | 14.732M | 8.604M |
| Interest Expense | 0.026M | - | 0.02M | 0.223M | 0M |
| Tax Provision | - | - | - | - | - |
| Interest Income | 1.519M | 0.03M | 0M | - | - |
| Net Interest Income | 1.519M | 0.03M | 0M | 0M | -0.019M |
| Income Tax Expense | - | - | -0.014M | 0.223M | -0.135M |
| Total Revenue | 0M | 0M | 0M | 0M | 0M |
| Total Operating Expenses | 13.938M | 2.823M | 7.386M | 14.732M | 8.604M |
| Cost Of Revenue | 0.055M | - | 0.072M | - | - |
| Total Other Income Expense Net | 1.708M | 0.021M | 0.014M | -0.223M | 0.108M |
| Net Income From Continuing Ops | -12.229M | -2.802M | -7.372M | -14.965M | -8.651M |
| Net Income Applicable To Common Shares | - | - | - | -14.965M | -8.651M |
Balance Sheet
(Currency in USD)| Breakdown | 30-09-2025 | 30-09-2024 | 30-09-2023 | 30-09-2022 | 30-09-2021 |
|---|---|---|---|---|---|
| Total Assets | 84.422M | 6.105M | 6.879M | 12.087M | 20.04M |
| Intangible Assets | - | - | - | - | 2000M |
| Other Current Assets | 0.988M | 0.217M | 0.028M | 0.164M | 0.168M |
| Total Liab | 2.377M | 0.568M | 0.281M | 1.544M | 0.639M |
| Total Stockholder Equity | 82.045M | 5.536M | 6.598M | 10.543M | 19.402M |
| Other Current Liab | 0.541M | 0.042M | 0.025M | 0.158M | 0.042M |
| Common Stock | 123.25M | 35.423M | 33.914M | 32.238M | 27.08M |
| Capital Stock | 123.25M | 35.423M | 33.914M | 32.238M | 27.08M |
| Retained Earnings | -46.578M | -34.349M | -31.547M | -24.175M | -9.21M |
| Good Will | - | - | - | - | -1999.998M |
| Other Assets | - | - | 0M | - | - |
| Cash | 82.909M | 5.72M | 6.748M | 11.628M | 19.76M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 2.335M | 0.529M | 0.281M | 1.472M | 0.639M |
| Current Deferred Revenue | - | - | - | - | - |
| Net Debt | -82.783M | -5.601M | -6.674M | -11.488M | -19.76M |
| Short Term Debt | 0.085M | 0.079M | 0.074M | 0.068M | - |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 0.126M | 0.119M | 0.074M | 0.14M | - |
| Other Stockholder Equity | - | 0.456M | 0.832M | 10542512M | -0.034M |
| Property Plant Equipment | - | - | - | 0.139M | - |
| Total Current Assets | 84.31M | 5.987M | 6.813M | 11.948M | 20.038M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 0.062M | - | 0.086M | - | - |
| Net Receivables | 0.413M | 0.05M | 0.037M | 0.156M | 0.11M |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | 1.71M | 0.408M | 0.182M | 1.246M | 0.597M |
| Accumulated Other Comprehensive Income | 5.373M | 4.006M | 3.399M | 2.479M | 1.565M |
| Non Currrent Assets Other | 0.032M | - | 0M | - | 0.002M |
| Non Current Assets Total | 0.112M | 0.118M | 0.066M | 0.139M | 0.002M |
| Capital Lease Obligations | 0.126M | 0.119M | 0.074M | 0.14M | - |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 30-09-2025 | 30-09-2024 | 30-09-2023 | 30-09-2022 | 30-09-2021 |
|---|---|---|---|---|---|
| Investments | - | - | - | - | - |
| Total Cashflows From Investing Activities | - | - | - | - | - |
| Total Cash From Financing Activities | 85.567M | 0.811M | 2.19M | 5.196M | 26.056M |
| Net Income | -12.229M | -2.802M | -7.372M | -14.965M | -8.651M |
| Change In Cash | 77.188M | -1.028M | -4.88M | -8.132M | 18.96M |
| Begin Period Cash Flow | 5.72M | 6.748M | 11.628M | 19.76M | 0.8M |
| End Period Cash Flow | 82.909M | 5.72M | 6.748M | 11.628M | 19.76M |
| Total Cash From Operating Activities | -8.692M | -1.85M | -7.024M | -13.587M | -7.319M |
| Depreciation | 0.077M | 0.073M | 0.072M | 0.006M | 0.006M |
| Other Cashflows From Investing Activities | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | - | - | - | - | - |
| Other Cashflows From Financing Activities | -0.36M | 0M | 1.058M | 1.168M | -1.689M |
| Capital Expenditures | 0M | 0M | 0M | 0M | 0M |
| Change In Working Capital | 0.555M | 0.04M | -0.942M | 0.726M | 0.306M |
| Other Non Cash Items | -0.277M | -0.001M | 0.065M | -0.23M | 0.145M |
| Free Cash Flow | -8.692M | -1.85M | -7.024M | -13.587M | -7.319M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | iShares Russell 2000 ETF | 2 months ago | 167141 |
| 2. | Heptagon Driehaus US Micro Cap Eq C$ Acc | 3 months ago | 104585 |
| 3. | Eventide Healthcare & Life Sciences I | 5 months ago | 103013 |
| 4. | BlackRock Health Sciences Opps Inv A | 3 months ago | 95655 |
| 5. | iShares Russell 2000 Growth ETF | 2 months ago | 56831 |
| 6. | Fidelity Small Cap Index | 4 months ago | 49024 |
| 7. | Driehaus Micro Cap Growth USD | 3 months ago | 42006 |
| 8. | State St Russell Sm/Mid Cp® Indx SL Cl I | 2 months ago | 40339 |
| 9. | Vanguard Russell 2000 ETF | 2 months ago | 34335 |
| 10. | Russell 2000 Equity Index Fund B | 5 months ago | 32011 |
| 11. | Driehaus Micro Cap Growth USD | 5 months ago | 30847 |
| 12. | Adara Smaller Companies | 2 months ago | 20238 |
| 13. | iShares Micro-Cap ETF | 2 months ago | 17477 |
| 14. | State St Russell Sm Cap® Indx SL Cl I | 3 months ago | 16100 |
| 15. | BlackRock Health Sciences Term Trust | 5 months ago | 15493 |
| 16. | Schwab Small Cap Index | 2 months ago | 15318 |
| 17. | NT R2000 Index Fund - NL | 2 months ago | 14924 |
| 18. | Stt Strt SPDR® Russell2000 US SmCapETF | 2 months ago | 13182 |
| 19. | AdvisorShares Psychedelics ETF | 2 months ago | 12613 |
| 20. | NT R2000 Index Fund - DC - NL - 3 | 2 months ago | 12222 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Cormorant Asset Management, LLC | 5 months ago | 1059331 |
| 2. | Vivo Capital, LLC | 5 months ago | 501617 |
| 3. | Perceptive Advisors LLC | 8 months ago | 449290 |
| 4. | Adage Capital Partners Gp LLC | 5 months ago | 395743 |
| 5. | BRAIDWELL LP | 5 months ago | 324358 |
| 6. | Driehaus Capital Management LLC | 5 months ago | 269641 |
| 7. | BlackRock Inc | 8 months ago | 234118 |
| 8. | MPM Oncology Impact Management LP | 5 months ago | 230147 |
| 9. | Balyasny Asset Management LLC | 5 months ago | 225412 |
| 10. | Millennium Management LLC | 5 months ago | 194437 |
| 11. | Morgan Stanley - Brokerage Accounts | 8 months ago | 192866 |
| 12. | Ikarian Capital, LLC | 5 months ago | 159421 |
| 13. | Eventide Asset Management, LLC | 5 months ago | 103013 |
| 14. | StemPoint Capital LP | 5 months ago | 97340 |
| 15. | Longwood Capital Partners LLC | 5 months ago | 84477 |
| 16. | Sio Capital Management, LLC | 5 months ago | 81883 |
| 17. | State Street Corp | 8 months ago | 68388 |
| 18. | Geode Capital Management, LLC | 5 months ago | 63546 |
| 19. | SEVEN GRAND MANAGERS, LLC | 5 months ago | 50000 |
| 20. | HHG PLC | 8 months ago | 1145660 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...